Award of NHS Framework Agreement for Branded Medicines in London – Tranche B

About

NHS England awarded a contract to AbbVie Ltd, Amgen Ltd, Astellas Pharma Ltd, Aventis Pharma Ltd trading as Sanofi, Bristol-Myers Squibb Pharmaceuticals Ltd., Daiichi Sankyo UK Ltd, ELI LILLY AND COMPANY LIMITED, Ferring Pharmaceutical, and Gedeo for the NHS Framework for the NHS London Region, Branded Medicines – Tranche B, covering Cytokine Modulators and other monoclonal Antibodies, and Antiretrovirals.

The contract value is £251,930,337.

The framework includes multiple offer references: CM/PHR/16/5515/01 from 1 September 2019 to 31 August 2021 with an option to extend up to 24 months; CM/PHR/16/5515/02 from 1 September 2019 to 31 August 2020 for Cytokine Modulators and other monoclonal antibodies with an option to extend up to 12 months; and CM/PHR/16/5515/03 from 1 September 2019 to 31 August 2020 for Antiretrovirals with an option to extend up to 12 months.